Metraipolis › archive › dc_23df2eb3b725

A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease — Europe PMC PMID:41478826

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41478826
DOI
10.1016/j.tjpad.2025.100458
License (as archived)
solo-consultazione
Archived
2026-11-07T05:45:28.414Z
SHA-256 of the archived text
f77c23608f6d17a7a1b3153d4f5d9dbe3502ed41e61ee9e01d05d4efeb8be0ed
Stable URL of this page
https://metraipolis.com/documento/dc_23df2eb3b725

How to cite

A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease — Europe PMC PMID:41478826 — Europe PMC (en), https://europepmc.org/article/MED/41478826 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_23df2eb3b725 (Metraipolis archive dc_23df2eb3b725, sha256 f77c23608f6d17a7a1b3153d4f5d9dbe3502ed41e61ee9e01d05d4efeb8be0ed)
BibTeX
@misc{dc23df2eb3b725,
  title = {A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease — Europe PMC PMID:41478826},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41478826},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_23df2eb3b725; sha256 f77c23608f6d17a7a1b3153d4f5d9dbe3502ed41e61ee9e01d05d4efeb8be0ed},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41478826. Agents can read the archived copy with the MCP tool read_document.